BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/23/2024 4:13:00 AM | Browse: 170 | Download: 505
 |
Received |
|
2023-11-20 02:15 |
|
Peer-Review Started |
|
2023-11-20 02:15 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-05 01:34 |
|
Revised |
|
2023-12-13 14:45 |
|
Second Decision |
|
2024-01-02 02:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-01-02 06:45 |
|
Articles in Press |
|
2024-01-02 06:45 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-13 12:57 |
|
Publish the Manuscript Online |
|
2024-01-23 04:13 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Clinical and Translational Research |
| Article Title |
Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yang Song, Hao-Jun Zhang, Xia Song, Jie Geng, Hong-Yi Li, Li-Zhong Zhang, Bo Yang and Xue-Chun Lu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Research and Development Program of China |
2021YFC2701704 |
|
| Corresponding Author |
Xue-Chun Lu, PhD, Chief Doctor, Professor, Research Scientist, Department of Hematology, the Second Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. luxuechun@301hospital.com.cn |
| Key Words |
Multiple myeloma; Functional enrichment analysis; Molecular docking simulation; Gene expression profiling; Therapeutic target; Ivermectin |
| Core Tip |
Multiple myeloma is a hematological malignancy with a significant impact on public health, and the t(4;14) subtype is particularly aggressive and resistant to existing treatments. Our study addresses the urgent need for new therapeutic approaches by employing a comprehensive approach that includes bioinformatics analysis, molecular docking, and experimental validation. We identified ten key genes associated with t(4;14) multiple myeloma (MM), shedding light on the molecular basis of this subtype. We explored the potential of ivermectin to assess whether it may be “repurposed” as a therapeutic agent for t(4;14) MM. Our findings indicate that ivermectin not only inhibits MM cell growth but also induces apoptosis via the nuclear factor-κB signaling pathway. |
| Publish Date |
2024-01-23 04:13 |
| Citation |
Song Y, Zhang HJ, Song X, Geng J, Li HY, Zhang LZ, Yang B, Lu XC. Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma. World J Clin Oncol 2024; 15(1): 115-129 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i1/115.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i1.115 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
